# Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease

> **NCT03702361** · PHASE4 · COMPLETED · sponsor: **Shaare Zedek Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Primary Disease

## Interventions

- **DRUG:** VPRIV

## Key facts

- **NCT ID:** NCT03702361
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-04
- **Primary completion:** 2019-09-30
- **Final completion:** 2021-03-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03702361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03702361, "Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03702361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*